Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
复制标题
DOI：
10.1056/nejmoa010845
复制
发表时间：
2001-09-27
影响因子：
158.5
通讯作者：
Finkelstein, JS
中科院分区：
文献类型：
--
作者：
Smith, MR;McGovern, FJ;Finkelstein, JS
背景资料：前列腺癌患者使用促性腺激素释放激素激动剂治疗可降低骨密度并增加骨折风险。我们进行了一项对照研究，预防骨质疏松症的男性接受治疗与促性腺激素释放激素激动剂。方法：在一项为期48周的开放标签研究，我们随机分配47名男性晚期或复发性前列腺癌，没有骨转移，接受单独亮丙瑞林或亮丙瑞林和帕米膦酸二钠（60毫克静脉注射，每12周）。双能X线骨密度仪测量腰椎和股骨近端的骨密度。通过定量计算机断层扫描测量腰椎的骨小梁密度。结果：在单独使用亮丙瑞林治疗的男性中，腰椎平均（+/-SE）骨密度降低3.3 ± 0.7%，转子降低2.1 ± 0.6%，全髋降低1.8 ± 0.4%，腰椎平均骨小梁密度降低8.5 ± 1.8%（P
Background: Treatment with a gonadotropin-releasing hormone agonist decreases bone mineral density and increases the risk of fracture in men with prostate cancer. We conducted a controlled study of the prevention of osteoporosis in men undergoing treatment with a gonadotropin-releasing hormone agonist.Methods: In a 48-week, open-label study, we randomly assigned 47 men with advanced or recurrent prostate cancer and no bone metastases to receive either leuprolide alone or leuprolide and pamidronate (60 mg intravenously every 12 weeks). Bone mineral density of the lumbar spine and the proximal femur was measured by dual-energy x-ray absorptiometry. Trabecular bone mineral density of the lumbar spine was measured by quantitative computed tomography. Forty-one men completed the study.Results: In men treated with leuprolide alone, the mean (+/-SE) bone mineral density decreased by 3.3+/-0.7 percent in the lumbar spine, 2.1+/-0.6 percent in the trochanter, and 1.8+/-0.4 percent in the total hip, and the mean trabecular bone mineral density of the lumbar spine decreased by 8.5+/-1.8 percent (P